Medigene AG to present at the 8th CAR-TCR Summit in Boston

August 1, 2026

Medigene AG, an immuno-oncology platform company specializing in T cell immunotherapies for solid tumors, will be presenting at the 8th CAR-TCR Summit in Boston from August 29 to September 1, 2023. The company’s Chief Scientific Officer, Prof. Dolores Schendel, is scheduled to speak on August 30, 2023.

Prof. Schendel's presentation is titled "Improving TCR-T Therapeutic Persistence & Efficacy with Switch Receptors," and is set to take place at 5:00 pm local time on the day of her presentation.

Medigene AG focuses on the development of T cell therapies aimed at effectively eliminating cancer. Its proprietary technology platform allows for the creation of T cell receptor engineered therapies optimized for both safety and efficacy across various solid tumor indications.

The company notes that its platform supports both in-house therapeutics and partnering opportunities. Medigene AG is publicly traded on the Frankfurt Stock Exchange under the ticker MDG1.

For further inquiries, interested parties can contact Pamela Keck at +49 89 2000 3333 01 or via email at investor@medigene.com. Additionally, Sandya von der Weid from LifeSci Advisors can be reached at +41 78 680 05 38 or svonderweid@lifesciadvisors.com.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.